– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib – – Breakthrough Therapy Designation is Based on Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 – – Company … [Read more…]

– First Preclinical Data for Pan-RAF Inhibitor DCC-3084 to be Presented; IND Filing Expected in Second Half of 2023 – – New Preclinical Data Supports ULK inhibitor DCC-3116 in Combination with QINLOCK® in GIST and in Combination with Encorafenib and Cetuximab in Colorectal Cancer; Expects to Initiate Two New Combination Escalation Studies in Second Half … [Read more…]

– Oral presentation highlights interim clinical data from Phase 1 dose escalation study of IO-108, a novel myeloid checkpoint inhibitor targeting LILRB2 (ILT4) as a monotherapy and in combination with pembrolizumab in patients with solid tumors – – Company announces late-breaking abstract from new preclinical program, IO-312, a novel LILRB4 x CD3 bispecific antibody for … [Read more…]

MELBOURNE, Australia–(BUSINESS WIRE)–Riskified (NYSE: RSKD) a leader in eCommerce risk intelligence, has been selected by Australia’s largest chain of retail pharmacies, Chemist Warehouse Group, as a trusted partner to protect its online store against fraudulent stolen card attacks and to grow eCommerce revenues by approving more legitimate orders. After experiencing cart abandonment and false decline … [Read more…]

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR … [Read more…]

PASADENA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that it will give an oral presentation highlighting the discovery of its clinical candidate FX-909, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in … [Read more…]

PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis to initiate in first half of 2023 KZR-261 dose escalation study currently enrolling sixth cohort; the dose expansion study expected to initiate in second half of 2023 Company to host a virtual Research and Development Day on March 15, 2023 Cash, cash equivalents and marketable … [Read more…]

The peer-reviewed study utilized the handheld Lumen device to accurately measure the impact of nutritional lifestyle on metabolic state NEW YORK–(BUSINESS WIRE)–#lumenmetabolism—Lumen, the metabolic health company behind the first handheld device to measure your metabolism through the breath, today announced a new peer-reviewed study conducted together with ARU Cambridge Center for Sport and Exercise Science, … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–#COVID19–Nearly 200 prominent leaders from around the world—including several presidents and prime ministers—have signed an open letter calling on governments to make a “never again” pledge and renounce pandemic profiteering and vaccine nationalism. AIDS Healthcare Foundation (AHF) supports the letter and echoes its conclusion, “It is time to embed justice, equity, and human … [Read more…]